2023 World Conference on Lung Cancer (Posters)-P2.18. Impact of Inclusion of Immunotherapy in National Treatment Guidelines on Survival Outcomes in Malignant Pleural Mesothelioma

P2.18. Impact of Inclusion of Immunotherapy in National Treatment Guidelines on Survival Outcomes in Malignant Pleural Mesothelioma - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to assess the impact of including immunotherapy (IO) in national treatment guidelines on survival outcomes in patients with malignant pleural mesothelioma (MPM). The authors analyzed data from the National Cancer Database (NCDB) spanning from 2004 to 2019. They compared the demographic, disease, and treatment characteristics of patients diagnosed between 2004-2012 and 2013-2019, and evaluated the effect of IO on overall survival (OS) using statistical tests.<br /><br />The results showed that there were 20,069 MPM diagnoses in the NCDB between 2004-2012 and 17,015 diagnoses between 2013-2019. The overall survival improved in the latter period, with a median OS of 11.79 months and 5-year OS of 13.5%, compared to a median OS of 9.49 months and 5-year OS of 8.4% in the earlier period. The diagnoses of epithelioid MPM increased significantly in the latter period.<br /><br />The number of patients receiving IO also increased each year, with 491 patients receiving IO in 2019 compared to only 12 patients in 2004. IO improved median OS by 5-7 months across all histologic groups, including epithelioid, biphasic, and sarcomatoid. Patients with epithelioid histology had a median OS of 15.04 months without IO and 20.63 months with IO. IO had the most notable improvement in OS in patients with sarcomatoid histology, with a median OS of 4.4 months without IO and 11.4 months with IO.<br /><br />In conclusion, the study found that IO has revolutionized the treatment of MPM. There has been a steady increase in the number of patients treated with IO over time, particularly after its inclusion in the NCCN guidelines in 2017. The overall survival for all patients treated with IO was 17.28 months, consistent with survival data from clinical trials. These findings highlight the positive impact of including IO in national treatment guidelines for MPM.

Asset Subtitle

Logan Roof

Meta Tag

Speaker Logan Roof

Topic Mesothelioma, Thymoma & Other Thoracic Tumors: Clinical

Keywords

immunotherapy

national treatment guidelines

survival outcomes

malignant pleural mesothelioma

National Cancer Database

epithelioid MPM

overall survival

histologic groups

NCCN guidelines